Journal Article

Trial of Lixisenatide in Early Parkinson’s Disease

Lefaucheur, Romain, Benard, Antoine, Meissner, Wassilios G., Drapier, Sophie, Marques, Ana, Catala, Hélène, Frismand-Kryloff, Solène, Mariani, Louise-Laure, Houéto, Jean-Luc, Boraud, Thomas, Remy, Philippe, Carrière, Nicolas, Damier, Philippe, Marse, Claire, Devos, David, Derkinderen, Pascal, Thiriez, Claire, Wyse, Richard K., Brefel-Courbon, Christine, Georget, Aurore, Ory-Magne, Fabienne, Maltête, David, Hardy, Clémence, Saubion, Amandine, Krystkowiak, Pierre, Tir, Mélissa, Anheim, Mathieu, Salhi, Hayet, Foubert-Samier, Alexandra, Rigalleau, Vincent, Corvol, Jean-Christophe, Dellapina, Estelle, Fabbri, Margherita, Hopes, Lucie, Giordana, Caroline, Benatru, Isabelle, Ferrier, Vanessa, Thalamas, Claire, Germain, Christine, Rascol, Olivier, Grimaldi, Stéphane, Stott, Simon R. W., Colin, Olivier, Laurens, Brice

2024

Overview

Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).

• Publisher: Massachusetts Medical Society
• Subject: Antiparkinson Agents - administration & dosage / Antiparkinson Agents - adverse effects / Antiparkinson Agents - therapeutic use / Clinical trials / Diabetes / Diabetes mellitus / Disease Progression / Dopamine / Double-Blind Method / Drug dosages / Endocrinology / GLP-1 receptor agonists / Glucagon / Glucagon-like peptide 1 / Glucagon-Like Peptide-1 Receptor Agonists - administration & dosage / Glucagon-Like Peptide-1 Receptor Agonists - adverse effects / Glucagon-Like Peptide-1 Receptor Agonists - therapeutic use / Humans / Injections, Subcutaneous / Insulin / Levodopa / Life Sciences / Motor Disorders - drug therapy / Neurodegenerative diseases / Neurology / Neurons and Cognition / Neuroprotection / Neuroprotective Agents - administration & dosage / Neuroprotective Agents - adverse effects / Neuroprotective Agents - therapeutic use / Neurosurgery / Pancreatitis / Parkinson Disease / Parkinson Disease - drug therapy / Parkinson's disease / Peptides / Peptides - administration & dosage / Peptides - adverse effects / Peptides - therapeutic use / Persons with Disabilities / Placebos / Treatment Outcome